XML 39 R26.htm IDEA: XBRL DOCUMENT
v3.25.3

Commitments and Contingencies (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Commitments and Contingencies Disclosure [Abstract] |
Schedule of Contractual Clinical Trials | Schedule of Contractual Clinical Trials
Description of Clinical Trial |  | Institution |  | Start Date |  | Projected End Date |  | Planned Number of Patients in Trial |  |  | Study Objective |  | Clinical Update |  | Expected Date of Preliminary Efficacy Signal |  | NCT No. |  | Remaining Financial Contractual Commitment |
LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2) |  | MD Anderson |  | January 2024 |  | December 2027 |  |  | 21 |  |  | Determine the OS of patients with recurrent ovarian clear cell carcinoma |  | 20 patients entered |  | December 2026 |  | NCT06065462 |  | $ | -0- (1 | )
LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b) |  | Netherlands Cancer Institute (NKI) |  | August 2024 |  | December 2026 |  |  | 37 |  |  | Determine RP2D with atezolizumab |  | First patient entered August 2024, in total two patients entered |  | June 2026 |  | NCT06012734 |  |  | -0- (1 | )
LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b) |  | GEIS |  | June 2023 |  | Recruitment completed September 2024 |  |  | 14 |  |  | Determine MTD and RP2D |  | Fourteen patients entered |  | December 2025 |  | NCT05809830 |  |  | 292,000 |
Total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 292,000 |
(1) | The Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.

X
- Definition Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Subparagraph (a) -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration